Neurology

Remyelination
#Financing #Multiple sclerosis #Neurology #Neuroscience #Rewind Therapeutics

New financing supports Rewind’s GPR17 remyelination programme

Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS).  MS is characterised by damage to myelin, but there are no approved therapies… Read More

#News

FDA
#FDA #Ionis Pharmaceuticals #Neurology #Rare disease

FDA approves first disease modifying treatment for Alexander disease

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ Zanvastro (zilganersen) for the treatment of Alexander disease (AxD) in paediatric and adult patients.   It is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic… Read More

#News #Regulatory

Neurons
#MindMaze Therapeutics #Neurology #Neuroscience

MindMaze Therapeutics refocuses efforts on neurology

MindMaze Therapeutics has announced the completion of its organisational simplification initiative, and the implementation of its CHF 8 ($9.8) million strategic equity financing with Neuro.io Group.  The company’s organisational simplification initiative included the selling of substantially all remaining non-neurology legacy operations acquired through its business combination with Relief Therapeutics.   The… Read More

#Business & Investment #News

#AstronauTx #Mergers and acquisitions #Neurology #Neuroscience

AstronauTx acquires neurological disease programme from Saniona

AstronauTx has secured the exclusive worldwide rights to research, develop, manufacture and commercialise therapeutic candidates arising from its collaboration with biopharma company Saniona.  Saniona and AstronauTx entered into a research collaboration and option agreement in 2023 to discover new treatments for neurological conditions by modulating a novel, undisclosed ion channel… Read More

#Business & Investment #News

Neurons in the brain
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Learn about neuroscience drug discovery in this free webinar

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Neuroscience concept
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Register now: The advances in neuroscience drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

How technology and science are driving neuroscience

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Webinar: Opportunities in neuroscience drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

DDW Neuroscience webinar: Opportunities for drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of new therapies… Read More

Webinar date:
Sponsored by BioIVT
#Webinars

Doctor examining brain MRI
#Clinical trial #Multiple sclerosis #Neurology #Pheno Therapeutics

Pheno Therapeutics heads towards human testing of MS therapy

Biotechnology company Pheno Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead therapeutic candidate PTD802 targeting multiple sclerosis (MS). The clearance follows a clinical trial authorisation (CTA) from the UK’s MHRA at the start… Read More

#News

MRI of the brain
#epilepsy #Neurology #University College London

EpilepsyGTx appoints Co-Founder Dimitri Kullman as CSO 

Biotechnology company EpilepsyGTx has appointed Professor Dimitri Kullman as Chief Scientific Officer.  As a Co-Founder of EpilepsyGTx, the company says Kullmann’s role as CSO will shape and execute scientific strategy, setting research priorities and overseeing the delivery of its pipeline programmes.  EpilepsyGTx sees Kullmann as an internationally recognised leader in… Read More

#News

#Multi-omics #Neurology

Companies aim to create largest ever neuro multi-omics dataset 

Biotechnology companies Valinor Discovery and Renew Biotechnologies have announced a strategic collaboration to generate what they say will be the largest clinical multi-omics dataset for neurological disorders.  Designed to improve the prediction of disease onset and therapeutic responses, the initiative aims to provide Valinor access to multimodal datasets derived from… Read More

#Business & Investment #News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Neuroscience Parkinson's disease
#Neurology #Norway #Parkinson's #Sweden

Parkinson’s could be identified in the blood, study shows 

Early signs of Parkinson’s disease can be identified in the blood, new research suggests.  In a new study published in npj Parkinson’s Disease, a research team from Chalmers University of Technology, Sweden and Oslo University Hospital, Norway identified biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. Read More

#News

#Financing #Investment #Neurology #OTR Therapeutics

OTR Therapeutics raises $100 million in series A financing

OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million Series A financing.   The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital.  Founded in March 2025, Shanghai-based OTR Therapeutics aims to discover and acquire… Read More

#Business & Investment #News #Start-up Zone